Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries
Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries

NCT05315323

CompletedN/A

Sponsor: AstraZeneca

Conditions: COVID-19

Countries: United Arab Emirates

Study on Clinical Use of EVUSHELD (AZD7442) as Pre-exposure Prophylaxis in the Real-world Setting - A Multi-Centre Observational Prospective Study to Determine the Utilization and Clinical Outcomes of EVUSHELD in Gulf Cooperation Council Countries

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Individuals receiving their first dose of AZD7442 for the prevention of SARS-CoV-2 infection within the 30 days prior to study enrolment.
* The ability or willingness to sign informed consent/assent forms

Exclusion Criteria:

* Patients currently participating in interventional clinical trials of SARS-CoV-2 vaccines, other SARS-CoV-2 prophylactic interventions, or COVID-19 treatments.
* Patients with an ongoing COVID-19 infection at the time of AZD7442 administration as judged by the study physician.
Locations (2)
  • Abu Dhabi, United Arab Emirates
  • Dubai, United Arab Emirates